EAM Investors’s Haemonetics HAE Stock Holding History

EAM Investors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-22,545	Closed	-$1.77M	–	303
2022 Q4	$1.77M	Sell	22,545 -3,987	-15%	-$320K	0.37%	113
2022 Q3	$1.96M	Buy	26,532 +4,082	+18%	+$293K	0.43%	90
2022 Q2	$1.46M	Buy	+22,450	New	+$1.33M	0.36%	112
2019 Q4	–	Sell	-17,369	Closed	-$2.19M	–	274
2019 Q3	$2.19M	Sell	17,369 -227	-1%	-$28.8K	0.58%	43
2019 Q2	$2.12M	Buy	+17,596	New	+$1.73M	0.52%	57
2019 Q1	–	Sell	-21,006	Closed	-$2.1M	–	282
2018 Q4	$2.1M	Sell	21,006 -14,521	-41%	-$1.53M	0.57%	42
2018 Q3	$4.07M	Sell	35,527 -2,701	-7%	-$280K	0.61%	29
2018 Q2	$3.43M	Sell	38,228 -3,851	-9%	-$325K	0.54%	54
2018 Q1	$3.08M	Buy	+42,079	New	+$2.89M	0.51%	80

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's HAE Position: Q1 2023 in Review

EAM Investors sold out of Haemonetics (HAE) in Q1 2023, closing a stake of 22,545 shares — an estimated $1.77M sold.

EAM Investors first reported a position in HAE in Q1 2018 and held it in 9 quarters. The position peaked at $4.07M in Q3 2018. 301 funds tracked by Wall St. Rank hold HAE as of Q1 2023.

EAM Investors reported no remaining Haemonetics position as of Q1 2023 after selling out during the quarter.
EAM Investors sold 22,545 Haemonetics shares in Q1 2023, an estimated $1.77M.
EAM Investors first reported a position in Haemonetics in Q1 2018 and held it in 9 quarters.
EAM Investors's Haemonetics position peaked at $4.07M in Q3 2018.
301 funds tracked by Wall St. Rank held Haemonetics as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.